Identification of β-lapachone analogs as novel MALT1 inhibitors to treat an aggressive subtype of diffuse large B-cell lymphoma

Journal of Medicinal Chemistry

Volumn 58, Issue 21, 2015, Pages 8491-8502

  Lim, Sang Min ^a   Jeong, Yujeong ^a,b   Lee, Suhyun ^a,b   Im, Honggu ^a,b   Tae, Hyun Seop ^a   Kim, Byung Gyu ^c   Park, Hee Dong ^c   Park, Jonghoon ^c   Hong, Sungwoo ^a,b  

^a Institute for Basic Science   (South Korea)

^b Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

^c LG Chemical Ltd   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 NAPHTHOQUINONE DERIVATIVE; BETA LAPACHONE; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA TRANSLOCATOR PROTEIN 1; ONCOPROTEIN; UNCLASSIFIED DRUG; 1,2-NAPHTHOQUINONE; ANTINEOPLASTIC AGENT; BETA-LAPACHONE; CASPASE; MALT1 PROTEIN, HUMAN; NAPHTHOQUINONE; TUMOR PROTEIN;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; B-CELL LYMPHOMA CELL LINE; CONTROLLED STUDY; COVALENT BOND; DRUG DESIGN; DRUG POTENCY; DRUG PROTEIN BINDING; HIGH THROUGHPUT SCREENING; JURKAT CELL LINE; LARGE CELL LYMPHOMA; PHARMACOPHORE; PHYSICAL CHEMISTRY; SIMULATION; STRUCTURE ACTIVITY RELATION; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; HUMAN; LYMPHOMA, LARGE B-CELL, DIFFUSE; METABOLISM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CASPASES; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MODELS, MOLECULAR; NAPHTHOQUINONES; NEOPLASM PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84947460168     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b01415     Document Type: Article

References (34)

1. Shaffer, A. L., 3rd; Young, R. M.; Staudt, L. M. Pathogenesis of human B cell lymphomas Annu. Rev. Immunol. 2012, 30, 565-610 10.1146/annurev-immunol-020711-075027
2. Nogai, H.; Dorken, B.; Lenz, G. Pathogenesis of non-Hodgkin's lymphoma J. Clin. Oncol. 2011, 29, 1803-1811 10.1200/JCO.2010.33.3252
3. Alizadeh, A. A.; Eisen, M. B.; Davis, R. E.; Ma, C.; Lossos, I. S.; Rosenwald, A.; Boldrick, J. C.; Sabet, H.; Tran, T.; Yu, X.; Powell, J. I.; Yang, L.; Marti, G. E.; Moore, T.; Hudson, J., Jr.; Lu, L.; Lewis, D. B.; Tibshirani, R.; Sherlock, G.; Chan, W. C.; Greiner, T. C.; Weisenburger, D. D.; Armitage, J. O.; Warnke, R.; Levy, R.; Wilson, W.; Grever, M. R.; Byrd, J. C.; Botstein, D.; Brown, P. O.; Staudt, L. M. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling Nature 2000, 403, 503-511 10.1038/35000501
4. Savage, K. J.; Monti, S.; Kutok, J. L.; Cattoretti, G.; Neuberg, D.; De Leval, L.; Kurtin, P.; Dal Cin, P.; Ladd, C.; Feuerhake, F.; Aguiar, R. C.; Li, S.; Salles, G.; Berger, F.; Jing, W.; Pinkus, G. S.; Habermann, T.; Dalla-Favera, R.; Harris, N. L.; Aster, J. C.; Golub, T. R.; Shipp, M. A. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma Blood 2003, 102, 3871-3879 10.1182/blood-2003-06-1841
5. Sinha, R.; DeJoubner, N.; Flowers, C. Novel agents for diffuse large B-cell lymphoma Expert Opin. Invest. Drugs 2011, 20, 669-680 10.1517/13543784.2011.565745
6. Rosenwald, A.; Wright, G.; Chan, W. C.; Connors, J. M.; Campo, E.; Fisher, R. I.; Gascoyne, R. D.; Muller-Hermelink, H. K.; Smeland, E. B.; Giltnane, J. M.; Hurt, E. M.; Zhao, H.; Averett, L.; Yang, L.; Wilson, W. H.; Jaffe, E. S.; Simon, R.; Klausner, R. D.; Powell, J.; Duffey, P. L.; Longo, D. L.; Greiner, T. C.; Weisenburger, D. D.; Sanger, W. G.; Dave, B. J.; Lynch, J. C.; Vose, J.; Armitage, J. O.; Montserrat, E.; Lopez-Guillermo, A.; Grogan, T. M.; Miller, T. P.; LeBlanc, M.; Ott, G.; Kvaloy, S.; Delabie, J.; Holte, H.; Krajci, P.; Stokke, T.; Staudt, L. M. Lymphoma/Leukemia Molecular Profiling, P., The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma N. Engl. J. Med. 2002, 346, 1937-1947 10.1056/NEJMoa012914
7. Wright, G.; Tan, B.; Rosenwald, A.; Hurt, E. H.; Wiestner, A.; Staudt, L. M. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma Proc. Natl. Acad. Sci. U. S. A. 2003, 100, 9991-9996 10.1073/pnas.1732008100
8. Lenz, G.; Davis, R. E.; Ngo, V. N.; Lam, L.; George, T. C.; Wright, G. W.; Dave, S. S.; Zhao, H.; Xu, W.; Rosenwald, A.; Ott, G.; Muller-Hermelink, H. K.; Gascoyne, R. D.; Connors, J. M.; Rimsza, L. M.; Campo, E.; Jaffe, E. S.; Delabie, J.; Smeland, E. B.; Fisher, R. I.; Chan, W. C.; Staudt, L. M. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma Science 2008, 319, 1676-1679 10.1126/science.1153629
9. Davis, R. E.; Ngo, V. N.; Lenz, G.; Tolar, P.; Young, R. M.; Romesser, P. B.; Kohlhammer, H.; Lamy, L.; Zhao, H.; Yang, Y.; Xu, W.; Shaffer, A. L.; Wright, G.; Xiao, W.; Powell, J.; Jiang, J. K.; Thomas, C. J.; Rosenwald, A.; Ott, G.; Muller-Hermelink, H. K.; Gascoyne, R. D.; Connors, J. M.; Johnson, N. A.; Rimsza, L. M.; Campo, E.; Jaffe, E. S.; Wilson, W. H.; Delabie, J.; Smeland, E. B.; Fisher, R. I.; Braziel, R. M.; Tubbs, R. R.; Cook, J. R.; Weisenburger, D. D.; Chan, W. C.; Pierce, S. K.; Staudt, L. M. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma Nature 2010, 463, 88-92 10.1038/nature08638
10. Compagno, M.; Lim, W. K.; Grunn, A.; Nandula, S. V.; Brahmachary, M.; Shen, Q.; Bertoni, F.; Ponzoni, M.; Scandurra, M.; Califano, A.; Bhagat, G.; Chadburn, A.; Dalla-Favera, R.; Pasqualucci, L. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma Nature 2009, 459, 717-721 10.1038/nature07968
11. Honma, K.; Tsuzuki, S.; Nakagawa, M.; Tagawa, H.; Nakamura, S.; Morishima, Y.; Seto, M. TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas Blood 2009, 114, 2467-2475 10.1182/blood-2008-12-194852
12. Ngo, V. N.; Young, R. M.; Schmitz, R.; Jhavar, S.; Xiao, W.; Lim, K. H.; Kohlhammer, H.; Xu, W.; Yang, Y.; Zhao, H.; Shaffer, A. L.; Romesser, P.; Wright, G.; Powell, J.; Rosenwald, A.; Muller-Hermelink, H. K.; Ott, G.; Gascoyne, R. D.; Connors, J. M.; Rimsza, L. M.; Campo, E.; Jaffe, E. S.; Delabie, J.; Smeland, E. B.; Fisher, R. I.; Braziel, R. M.; Tubbs, R. R.; Cook, J. R.; Weisenburger, D. D.; Chan, W. C.; Staudt, L. M. Oncogenically active MYD88 mutations in human lymphoma Nature 2011, 470, 115-119 10.1038/nature09671
13. Ngo, V. N.; Davis, R. E.; Lamy, L.; Yu, X.; Zhao, H.; Lenz, G.; Lam, L. T.; Dave, S.; Yang, L.; Powell, J.; Staudt, L. M. A loss-of-function RNA interference screen for molecular targets in cancer Nature 2006, 441, 106-110 10.1038/nature04687
14. Coornaert, B.; Baens, M.; Heyninck, K.; Bekaert, T.; Haegman, M.; Staal, J.; Sun, L.; Chen, Z. J.; Marynen, P.; Beyaert, R. T cell antigen receptor stimulation induces MALT1 paracaspase-mediated cleavage of the NF-kappaB inhibitor A20 Nat. Immunol. 2008, 9, 263-271 10.1038/ni1561
15. Staal, J.; Driege, Y.; Bekaert, T.; Demeyer, A.; Muyllaert, D.; Van Damme, P.; Gevaert, K.; Beyaert, R. T-cell receptor-induced JNK activation requires proteolytic inactivation of CYLD by MALT1 EMBO J. 2011, 30, 1742-1752 10.1038/emboj.2011.85
16. Ferch, U.; Kloo, B.; Gewies, A.; Pfander, V.; Duwel, M.; Peschel, C.; Krappmann, D.; Ruland, J. Inhibition of MALT1 protease activity is selectively toxic for activated B cell-like diffuse large B cell lymphoma cells J. Exp. Med. 2009, 206, 2313-2320 10.1084/jem.20091167
17. Hailfinger, S.; Lenz, G.; Ngo, V.; Posvitz-Fejfar, A.; Rebeaud, F.; Guzzardi, M.; Penas, E. M.; Dierlamm, J.; Chan, W. C.; Staudt, L. M.; Thome, M. Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma Proc. Natl. Acad. Sci. U. S. A. 2009, 106, 19946-19951 10.1073/pnas.0907511106
18. Nagel, D.; Spranger, S.; Vincendeau, M.; Grau, M.; Raffegerst, S.; Kloo, B.; Hlahla, D.; Neuenschwander, M.; Peter von Kries, J.; Hadian, K.; Dorken, B.; Lenz, P.; Lenz, G.; Schendel, D. J.; Krappmann, D. Pharmacologic inhibition of MALT1 protease by phenothiazines as a therapeutic approach for the treatment of aggressive ABC-DLBCL Cancer Cell 2012, 22, 825-837 10.1016/j.ccr.2012.11.002
19. Fontan, L.; Yang, C.; Kabaleeswaran, V.; Volpon, L.; Osborne, M. J.; Beltran, E.; Garcia, M.; Cerchietti, L.; Shaknovich, R.; Yang, S. N.; Fang, F.; Gascoyne, R. D.; Martinez-Climent, J. A.; Glickman, J. F.; Borden, K.; Wu, H.; Melnick, A. MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo Cancer Cell 2012, 22, 812-824 10.1016/j.ccr.2012.11.003
20. Yu, J. W.; Jeffrey, P. D.; Ha, J. Y.; Yang, X.; Shi, Y. Crystal structure of the mucosa-associated lymphoid tissue lymphoma translocation 1 (MALT1) paracaspase region Proc. Natl. Acad. Sci. U. S. A. 2011, 108, 21004-21009 10.1073/pnas.1111708108
21. Takuwa, A.; Soga, O.; Iwamoto, H.; Maruyama, K. The Addition of Alcohol to 1,2-Naphthoquinone Promoted by Metal-Ions-a Facile Synthesis of 4-Alkoxy-1,2-Naphthoquinones Bull. Chem. Soc. Jpn. 1986, 59, 2959-2961 10.1246/bcsj.59.2959
22. Hooker, S. C. LVII.-The constitution of "lapachic acid"(lapachol) and its derivatives J. Chem. Soc., Trans. 1892, 61, 611-650 10.1039/ct8926100611
23. Park, H.; Shin, Y.; Choe, H.; Hong, S. Computational Design and Discovery of Nanomolar Inhibitors of IκB Kinase β J. Am. Chem. Soc. 2015, 137, 337-348 10.1021/ja510636t
24. Park, H.; Hong, S.; Kim, J.; Hong, S. Discovery of Picomolar ABL Kinase Inhibitors Equipotent for Wild Type and T315I Mutant via Structure-Based de novo Design J. Am. Chem. Soc. 2013, 135, 8227-8237 10.1021/ja311756u
25. Hussain, H.; Krohn, K.; Ahmad, V. U.; Miana, G. A.; Green, I. R. Lapachol: an overview ARKIVOC 2007, 145-171
26. Manna, S. K.; Gad, Y. P.; Mukhopadhyay, A.; Aggarwal, B. B. Suppression of tumor necrosis factor-activated nuclear transcription factor-kappaB, activator protein-1, c-Jun N-terminal kinase, and apoptosis by beta-lapachone Biochem. Pharmacol. 1999, 57, 763-774 10.1016/S0006-2952(98)00354-2
27. Moon, D. O.; Choi, Y. H.; Kim, N. D.; Park, Y. M.; Kim, G. Y. Anti-inflammatory effects of beta-lapachone in lipopolysaccharide-stimulated BV2 microglia Int. Immunopharmacol. 2007, 7, 506-514 10.1016/j.intimp.2006.12.006
28. Li, Y.; Sun, X.; LaMont, J. T.; Pardee, A. B.; Li, C. J. Selective killing of cancer cells by beta -lapachone: direct checkpoint activation as a strategy against cancer Proc. Natl. Acad. Sci. U. S. A. 2003, 100, 2674-2678 10.1073/pnas.0538044100
29. Bey, E. A.; Bentle, M. S.; Reinicke, K. E.; Dong, Y.; Yang, C. R.; Girard, L.; Minna, J. D.; Bornmann, W. G.; Gao, J.; Boothman, D. A. An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone Proc. Natl. Acad. Sci. U. S. A. 2007, 104, 11832-11837 10.1073/pnas.0702176104
30. Li, L. S.; Bey, E. A.; Dong, Y.; Meng, J.; Patra, B.; Yan, J.; Xie, X. J.; Brekken, R. A.; Barnett, C. C.; Bornmann, W. G.; Gao, J.; Boothman, D. A. Modulating endogenous NQO1 levels identifies key regulatory mechanisms of action of beta-lapachone for pancreatic cancer therapy Clin. Cancer Res. 2011, 17, 275-285 10.1158/1078-0432.CCR-10-1983
31. Buckle, D. R.; Cantello, B. C.; Smith, H.; Smith, R. J.; Spicer, B. A. Synthesis and antiallergic activity of 2-hydroxy-3-nitro-1,4-naphthoquinones J. Med. Chem. 1977, 20, 1059-1064 10.1021/jm00218a014
32. Jo, I. G.; Yoo, S.-K.; Park, M.-G.; Kwak, T., Pharmaceutical composition containing naphthoquinone-based compound for intestine delivery system. EP2094261 A1, 2007.
33. Bian, J.; Deng, B.; Zhang, X.; Hu, T.; Wang, N.; Wang, W.; Pei, H.; Xu, Y.; Chu, H.; Li, X.; Sun, H.; You, Q. Lewis acid mediated highly regioselective intramolecular cyclization for the synthesis of β-lapachone Tetrahedron Lett. 2014, 55, 1475-1478 10.1016/j.tetlet.2014.01.059
34. Rebeaud, F.; Hailfinger, S.; Posevitz-Fejfar, A.; Tapernoux, M.; Moser, R.; Rueda, D.; Gaide, O.; Guzzardi, M.; Iancu, E. M.; Rufer, N.; Fasel, N.; Thome, M. The proteolytic activity of the paracaspase MALT1 is key in T cell activation Nat. Immunol. 2008, 9, 272-281 10.1038/ni1568